drugset / Trial / NCT06095674
ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study
Phase 1
Unknown
30 enrolled
Academic Medical Center - University of Amsterdam
Agenus Inc. · collabDutch Cancer Society · collab
NaSingle-groupOpen-labelTreatment
Summary
The ITHACA study is a phase I study evaluating the safety and toxicity of a peritumorally injected PD-1 checkpoint inhibitor, in combination with a multifunctional CTLA-4 inhibitor, in early-stage cervical cancer.
Timeline
- Start
- 2024-01
- Primary completion
- 2026-01
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balstilimab | Monoclonal antibody | — | Other |
| Subject | Botensilimab | Monoclonal antibody | — | Other |